These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8806 related articles for article (PubMed ID: 15819587)

  • 1. Improving outcomes in advanced malignant melanoma: update on systemic therapy.
    Danson S; Lorigan P
    Drugs; 2005; 65(6):733-43. PubMed ID: 15819587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
    Bedikian AY; Millward M; Pehamberger H; Conry R; Gore M; Trefzer U; Pavlick AC; DeConti R; Hersh EM; Hersey P; Kirkwood JM; Haluska FG;
    J Clin Oncol; 2006 Oct; 24(29):4738-45. PubMed ID: 16966688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-2 for the treatment of melanoma.
    Tarhini AA; Agarwala SS
    Curr Opin Investig Drugs; 2005 Dec; 6(12):1234-9. PubMed ID: 16370388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
    Flaherty LE
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
    Egberts F; Kahler KC; Livingstone E; Hauschild A
    Onkologie; 2008 Jul; 31(7):398-403. PubMed ID: 18596389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'.
    Bedikian AY; Garbe C; Conry R; Lebbe C; Grob JJ;
    Melanoma Res; 2014 Jun; 24(3):237-43. PubMed ID: 24667300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
    Agarwala SS; Keilholz U; Gilles E; Bedikian AY; Wu J; Kay R; Stein CA; Itri LM; Suciu S; Eggermont AM
    Eur J Cancer; 2009 Jul; 45(10):1807-14. PubMed ID: 19419855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
    Carvajal RD; Schwartz GK; Mann H; Smith I; Nathan PD
    BMC Cancer; 2015 Jun; 15():467. PubMed ID: 26059332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current treatment options for malignant melanoma.
    Cohen GL; Falkson CI
    Drugs; 1998 Jun; 55(6):791-9. PubMed ID: 9617594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy for Melanoma.
    Wilson MA; Schuchter LM
    Cancer Treat Res; 2016; 167():209-29. PubMed ID: 26601864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upcoming strategies for the treatment of metastatic melanoma.
    Spagnolo F; Queirolo P
    Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
    Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic chemotherapy.
    Klimek VM; Wolchok JD; Chapman PB; Houghton AN; Hwu WJ
    Clin Plast Surg; 2000 Jul; 27(3):451-61, ix-x. PubMed ID: 10941565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New drugs in melanoma: it's a whole new world.
    Eggermont AM; Robert C
    Eur J Cancer; 2011 Sep; 47(14):2150-7. PubMed ID: 21802280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous melanoma: available therapy for metastatic disease.
    Tarhini AA; Agarwala SS
    Dermatol Ther; 2006; 19(1):19-25. PubMed ID: 16405566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab: A Review in Advanced Melanoma.
    Scott LJ
    Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
    McDermott DF; Sosman JA; Gonzalez R; Hodi FS; Linette GP; Richards J; Jakub JW; Beeram M; Tarantolo S; Agarwala S; Frenette G; Puzanov I; Cranmer L; Lewis K; Kirkwood J; White JM; Xia C; Patel K; Hersh E
    J Clin Oncol; 2008 May; 26(13):2178-85. PubMed ID: 18445842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
    Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
    J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model.
    Heere-Ress E; Boehm J; Thallinger C; Hoeller C; Wacheck V; Birner P; Wolff K; Pehamberger H; Jansen B
    J Invest Dermatol; 2005 Aug; 125(2):201-6. PubMed ID: 16098027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 441.